Search

Your search keyword '"Kodama, Hiroaki"' showing total 465 results
Start Over Author "Kodama, Hiroaki" Publication Type Academic Journals
465 results on '"Kodama, Hiroaki"'

1. The efficacy and safety of anamorelin among patients with diabetes

Author

Ando, Kenju, Naito, Tateaki, Hamauchi, Satoshi, Miura, Keita, Nishibori, Yuichiro, Tonsho, Ayumi, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ryo, Ko, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Yamazaki, Kentaro, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

4. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing

Author

Wakuda, Kazushige, Morita, Meiko, Sekikawa, Motoki, Morikawa, Noboru, Miura, Keita, Doshita, Kosei, Iida, Yuko, Kodama, Hiroaki, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Muramatsu, Koji, Kawata, Takuya, Mori, Keita, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

6. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study

Author

Morikawa, Noboru, Naito, Tateaki, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Yabe, Michitoshi, Kodama, Hiroaki, Miura, Keita, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

8. An agroecological structure model of compost—soil—plant interactions for sustainable organic farming

Author

Miyamoto, Hirokuni, Shigeta, Katsumi, Suda, Wataru, Ichihashi, Yasunori, Nihei, Naoto, Matsuura, Makiko, Tsuboi, Arisa, Tominaga, Naoki, Aono, Masahiko, Sato, Muneo, Taguchi, Shunya, Nakaguma, Teruno, Tsuji, Naoko, Ishii, Chitose, Matsushita, Teruo, Shindo, Chie, Ito, Toshiaki, Kato, Tamotsu, Kurotani, Atsushi, Shima, Hideaki, Moriya, Shigeharu, Wada, Satoshi, Horiuchi, Sankichi, Satoh, Takashi, Mori, Kenichi, Nishiuchi, Takumi, Miyamoto, Hisashi, Kodama, Hiroaki, Hattori, Masahira, Ohno, Hiroshi, Kikuchi, Jun, and Hirai, Masami Yokota

Published
2023
Full Text
View/download PDF

10. Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study

Author

Nishibori, Yuichiro, Kenmotsu, Hirotsugu, Ando, Kenju, Tonsho, Ayumi, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Morikawa, Noboru, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

11. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma

Author

Hazama, Daisuke, Nakahama, Kenji, Kodama, Hiroaki, Miyazaki, Akito, Azuma, Koichi, Kawashima, Yosuke, Sato, Yuki, Ito, Kentaro, Shiraishi, Yoshimasa, Miura, Keita, Takahama, Takayuki, Oizumi, Satoshi, Namba, Yoshinobu, Ikeda, Satoshi, Yoshioka, Hiroshige, Tsuya, Asuka, Yasuda, Yuichiro, Negi, Yoshiki, Hara, Ayako, Toda, Michihito, and Tachihara, Motoko

Published
2024
Full Text
View/download PDF

12. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

Author

Nakamura, Atsushi, Yamaguchi, Ou, Mori, Keita, Miura, Keita, Tamiya, Motohiro, Oba, Tomohiro, Yanagitani, Noriko, Mizutani, Hideaki, Ninomiya, Takashi, Kajiwara, Tomosue, Ito, Kentaro, Miyanaga, Akihiko, Arai, Daisuke, Kodama, Hiroaki, Kobayashi, Kunihiko, and Kaira, Kyoichi

Published
2023
Full Text
View/download PDF

13. Noninvasive fecal metabolic profiling for the evaluation of characteristics of thermostable lactic acid bacteria, Weizmannia coagulans SANK70258, for broiler chickens

Author

Ito, Kayo, Miyamoto, Hirokuni, Matsuura, Makiko, Ishii, Chitose, Tsuboi, Arisa, Tsuji, Naoko, Nakaguma, Teruno, Nakanishi, Yumiko, Kato, Tamotsu, Suda, Wataru, Honda, Fuyuko, Ito, Toshiyuki, Moriya, Shigeharu, Shima, Hideaki, Michibata, Ryounosuke, Yamada, Ryouichi, Takahashi, Yosuke, Koga, Hirohisa, Kodama, Hiroaki, Watanabe, Yuko, Kikuchi, Jun, and Ohno, Hiroshi

Published
2022
Full Text
View/download PDF

14. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

Author

Doshita, Kosei, Kenmotsu, Hirotsugu, Omori, Shota, Tabuchi, Yuya, Kawabata, Takanori, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Iida, Yuko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Kaneko, Takeshi, and Takahashi, Toshiaki

Published
2022
Full Text
View/download PDF

16. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.

Author

Doshita, Kosei, Naito, Tateaki, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Murakami, Haruyasu, Kenmotsu, Hirotsugu, and Takahashi, Toshiaki

Subjects
THERAPEUTIC use of antineoplastic agents, ANOREXIA nervosa treatment, CANCER relapse, ANTINEOPLASTIC agents, TREATMENT effectiveness, RETROSPECTIVE studies, CANCER patients, LUNGS, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, CANCER chemotherapy, LUNG tumors, ANOREXIA nervosa, MEDICAL records, ACQUISITION of data, LUNG cancer, PROGRESSION-free survival, COMPARATIVE studies, OVERALL survival, PLATINUM, DISEASE complications
Abstract

Background: Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy‐induced anorexia and therapeutic outcomes in patients with stage IV non‐small‐cell lung cancer undergoing platinum‐based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non‐small‐cell lung cancer treated with platinum‐based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy‐induced anorexia group. Chemotherapy‐induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression‐free and overall survival were used to measure treatment efficacy. Results: Chemotherapy‐induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non‐chemotherapy‐induced anorexia group. Progression‐free and overall survival were shorter in the chemotherapy‐induced anorexia group than in the non‐chemotherapy‐induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy‐induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non‐small‐cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy‐induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum‐based chemotherapy combined with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer.

Author

Morita, Meiko, Ono, Akira, Sekikawa, Motoki, Doshita, Kosei, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Isaka, Mitsuhiro, Ohde, Yasuhisa, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

20. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma

Author

Kodama, Hiroaki, Wakuda, Kazushige, Yabe, Michitoshi, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

21. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy

Author

Mamesaya, Nobuaki, Muramatsu, Koji, Yabe, Michitoshi, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Taichi, Miyawaki, Eriko, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Harada, Hideyuki, Sugino, Takashi, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

22. Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer.

Author

Kodama, Hiroaki, Murakami, Haruyasu, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Matsumoto, Shingo, Goto, Koichi, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
*RNA analysis, *DNA analysis, *CYTOLOGY, *CANCER treatment, *POLYMERASE chain reaction, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *FROZEN tissue sections, *LUNG cancer, *COLLECTION & preservation of biological specimens, *SENSITIVITY & specificity (Statistics), *SPECIALTY hospitals, *SEQUENCE analysis, *EPIDERMAL growth factor receptors
Abstract

Background: The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non‐small cell lung cancer (NSCLC). However, the suitability of cytology specimens as samples for the AmoyDx PLC panel remains unclear. We evaluated the performance of frozen cell pellets from cytology specimens (FCPs) in the Amoy 9‐in‐1 assay, a preapproval assay of the AmoyDx PLC panel. Methods: We retrospectively collected data of NSCLC patients enrolled in LC‐SCRUM‐Asia from the Shizuoka Cancer Center between September 2019 and May 2021. Results: A total of 49 cases submitted FCPs for evaluation of oncogenic driver alterations and were assessed using Amoy 9‐in‐1 and next‐generation sequencing (NGS) assays. The success rates of DNA and RNA analyses using the Amoy 9‐in‐1 were both 100%, compared with 86% and 45%, respectively, using NGS assays. Oncogenic driver alterations were detected in 27 (55%) and 23 (47%) patients using Amoy 9‐in‐1 and NGS, respectively. No inconsistent results were observed among 19 cases in which both assays showed successful detection. In the remaining 30 cases, 10 had inconsistent results: nine oncogenic driver alterations (3 MET, 2 ALK, 2 ROS1, and 2 KRAS) were detectable only in Amoy 9‐in‐1, and one epidermal growth factor receptor (EGFR) mutation was detectable only in NGS. Conclusion: FCPs can be successfully used in the AmoyDx PLC panel, with higher success rate compared with the NGS assay. The AmoyDx PLC panel may be an option in cases when insufficient tissue sample is available for the NGS assay. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Author

Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

31. Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.

Author

Iida, Yuko, Wakuda, Kazushige, Kawata, Takuya, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Yabe, Michitoshi, Kodama, Hiroaki, Miura, Keita, Morikawa, Noboru, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
BIOMARKERS, DRUG efficacy, CHROMOGRANINS, IMMUNE checkpoint inhibitors, NEUROENDOCRINE system, SPECIALTY hospitals, SMALL cell carcinoma, IMMUNOHISTOCHEMISTRY, CANCER chemotherapy, LUNG tumors, RETROSPECTIVE studies, ANTINEOPLASTIC agents, CANCER treatment, PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Background: Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohistochemical neuroendocrine (NE) markers (synaptophysin, chromogranin A, and neural cell adhesion molecule [NCAM]). In the present study, we aimed to analyze the relationship between the expression of immunohistochemical NE markers and the efficacy of ICIs in patients with extensive disease (ED)‐SCLC, to assess whether conventional NE markers are predictive of ICIs. Methods: Patients with untreated ED‐SCLC who received first‐line therapy at the Shizuoka Cancer Center between November 2002 and July 2021 were retrospectively reviewed. We evaluated the efficacy of first‐line chemotherapy according to the expression status of each immunohistochemical NE marker in patients treated with ICI plus chemotherapy (ICI‐chemo group) and with chemotherapy alone (chemo group). Results: A total of 227 patients were included in the ICI‐chemo and chemo groups, respectively. The progression‐free survival (PFS) tended to be better in patients in the ICI‐chemo group than those treated with chemotherapy alone in patients with NE marker‐positive SCLC. In particular, it was statistically significant in patients with chromogranin A‐positive SCLC (p = 0.036). In patients with NE marker‐negative SCLC, no significant differences were observed in PFS between the two groups. There were no significant differences in overall survival (OS), regardless of the expression of any conventional NE marker. Conclusion: Our study suggests that the efficacy of ICIs in addition to chemotherapy may be poor in patients with NE marker‐negative SCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer.

Author

Sekikawa, Motoki, Murakami, Haruyasu, Morita, Meiko, Doshita, Kosei, Miura, Keita, Kodama, Hiroaki, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Chiba, Hirofumi, and Takahashi, Toshiaki

Subjects
LUNG cancer, ANTHRACYCLINES, GRANULOCYTE-colony stimulating factor, FEBRILE neutropenia, CANCER chemotherapy, ANTINEOPLASTIC agents, RETROSPECTIVE studies, TREATMENT effectiveness, CANCER patients, PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Background: Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and efficacy of AMR with primary prophylactic pegfilgrastim (P‐PEG) have not been sufficiently evaluated. In this study, we evaluated the safety and efficacy of AMR with or without P‐PEG as second‐line chemotherapy for SCLC. Methods: We retrospectively reviewed patients with SCLC who received AMR as second‐line chemotherapy at Shizuoka Cancer Center, between December 2014 and November 2021. Based on presence/absence of P‐PEG in their regimen, patients (n = 60) were divided into P‐PEG (n = 21) and non‐P‐PEG groups, and their clinical outcomes were evaluated. Results: Median of AMR treatment cycles was five (range: 1–39 cycles) in P‐PEG group and four (range: 1–15 cycles) in non‐P‐PEG group. The incidence of FN (4.8% vs. 30.8%; p = 0.02) and AMR dose reduction because of adverse events (4.8% vs. 25.6%; p = 0.08) were lower in the P‐PEG group than in the non‐P‐PEG group. The objective response rates were 52.4% and 30.8%, and median progression‐free and overall survival were 4.7 and 3.0 months, and 9.6 and 6.8 months, in the P‐PEG and non‐P‐PEG groups, respectively. Conclusions: AMR with P‐PEG as second‐line chemotherapy for SCLC reduced the incidence of FN at a maintained AMR dose intensity and was associated with favorable tumor responses and survival outcomes. P‐PEG should be considered for patients treated with AMR for SCLC including refractory relapsed SCLC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. A Thermophile-Fermented Compost Modulates Intestinal Cations and the Expression of a Juvenile Hormone-Binding Protein Gene in the Female Larvae of Hercules Beetle Dynastes hercules (Coleoptera: Scarabaeidae).

Author

Asano, Futo, Miyahara, Taira, Miyamoto, Hirokuni, and Kodama, Hiroaki

Subjects
GENE expression, SCARABAEIDAE, COMPOSTING, POTASSIUM ions, LARVAE, INTESTINES, BEETLES
Abstract

Simple Summary: Various rhino and stag beetles are popular as pets, and their large adults are especially attractive. The female Hercules beetle larvae reared in humus supplemented with a thermophile-fermented compost showed improved growth. Feeding with compost increased the concentration of midgut potassium ions, which was associated with the production of a fermentative unidentified organic acid. Interestingly, adding compost to the humus induced the expression of a gene encoding a hemolymph juvenile hormone-binding protein. Our results suggested that a diet containing fermentative bacteria sex-dependently controls the hormonal condition of saprophagous beetle larvae. The Hercules beetle larvae grow by feeding on humus, and adding a thermophile-fermented compost to the humus can upregulate the growth of female larvae. In this study, the effects of compost on the intestinal environment, including pH, cation concentrations, and organic acid concentrations of intestinal fluids, were investigated, and the RNA profile of the fat body was determined. Although the total intestinal potassium ions were similar between the larvae grown without compost (control larvae) and those with compost (compost larvae), the proportion of potassium ions in the midgut of the compost larvae drastically increased. In the midgut, an unidentified organic acid was the most abundant, and its concentration increased in the compost larvae. Transcriptome analysis showed that a gene encoding hemolymph juvenile-binding protein (JHBP) was expressed in the compost female larvae and not in the control female larvae. Expression of many genes involved in the defensive system was decreased in the compost female larvae. These results suggest that the female-specific enhancement of larval growth by compost was associated with the increased JHBP expression under conditions in which the availability of nutrition from the humus was improved by an increase in potassium ions in the midgut. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status.

Author

Mamesaya, Nobuaki, Kodama, Hiroaki, Iida, Yuko, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
*ETOPOSIDE, *DRUG efficacy, *CARBOPLATIN, *FEBRILE neutropenia, *GRANULOCYTE-colony stimulating factor, *SMALL cell carcinoma, *FUNCTIONAL status, *LUNG tumors, *RETROSPECTIVE studies, *COMPARATIVE studies, *CANCER patients, *NEUTROPHILS, *DESCRIPTIVE statistics, *PROGRESSION-free survival, *OVERALL survival, *EVALUATION, *OLD age
Abstract

Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However, older patients often exhibit poor PS (3, 4), and the treatment effect in them is poorly understood. To determine the therapeutic efficacy and safety of carboplatin plus etoposide therapy for this population, we retrospectively analyzed 63 patients with ES‐SCLC with PS ≥2, aged ≥71 years, who had received first‐line carboplatin plus etoposide therapy. We compared the treatment efficacy and safety in patients with baseline PS 2 versus those with PS 3–4. In the PS 2 (38 patients) and PS ≥3 (25 patients) groups, the overall response rate was 71.1% and 72.0%, median progression‐free survival was 4.6 and 3.1 months, and overall survival was 7.7 and 5.1 months, respectively. PS improved to 0–1 post‐treatment in 65.8% and 48.0% of the patients in the PS 2 and PS ≥3 groups, respectively. Patients with PS ≥3 showing improved PS had a progression‐free survival of 6.1 months. A higher incidence of grade ≥3 decreased neutrophil counts, febrile neutropenia, and treatment‐related death was observed in the PS ≥3 group. The progression‐free survival of patients administered prophylactic granulocyte colony‐stimulating factor (G‐CSF) was 5.2 and 6.1 months in the PS2 and PS ≥3 groups. Overall, carboplatin plus etoposide therapy provided comparable tumor shrinkage, but shorter progression‐free and overall survival in older ES‐SCLC patients with PS ≥3 than in those with PS 2. Thus, supportive care, such as prophylactic G‐CSF administration, may be necessary to ensure safety and survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results